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A number of natural cytokines are characterized as having dipeptidyl peptidase (DP) IV susceptible N-terminal peptide sequences. Here we 
demonstrate that oligopeptides with sequences analogous to the N-terminal part of human IL-IS, IL-2, TNF-B and murine IL-6 were hydrolyzed 
by purified DP IV and aminopeptidase N (AP-N). The rate of DP IV-catalyzed hydrolysis of these peptides was negatively correlated with their 
chain length. In contrast o these results, no degradation was found under our conditions for the intact recombinant cytokines, IL-la, IL-l/?, IL-2, 
G-CSF and for natural IL-2, independent of whether DP IV and AP-N were used separately or in combination. 
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1. INTRODUCTION 
Recent data in the literature have provided evidence 
that proteolytic enzymes are involved in the regulation 
of release [14], modification [5-81, and inactivation [9] 
of cytokines. 
Special interest has been focussed on peptidases 
which are localized on the plasma membrane of immune 
cells, e.g. dipeptidyl peptidase IV (DP IV, CD26, EC 
3.4.14.5) and aminopeptidase N (AP-N, CD13, EC 
3.4.11.2), because these ectopeptidases are candidates 
for direct interaction with cytokines and their receptors. 
DP IV is an exopeptidase releasing dipeptides with a 
X-Pro(Ala) sequence from the N-terminal part [lo]. 
AP-N is able to split off amino acids from the N-termi- 
nus, with the exception of proline in the penultimate 
position [l 11. Data from our and other laboratories 
have shown that these membrane-bound exopeptidases 
are involved in the regulation of lymphocyte activation 
and immune response [12-201. However, their physio- 
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MNC, mononuclear cells; nIL, natural interleukin; POE, polyoxy- 
ethylene; rIL, recombinant interleukin; TGF-p, transforming growth 
factor; TNF, tumour necrosis factor. 
logical substrates in the immune system are as yet un- 
known. 
Interestingly, many of natural cytokines, e.g. IL-l/?, 
IL-2, IL-3, IL-6, TNF-/?, GM-CSF and G-CSF, have 
N-terminal sequences with proline in the second posi- 
tion. In the case of other cytokines, e.g. IL-l&, interfer- 
ons and recombinant cytokines, proline is localized in 
the third or later position of the N-terminus. In these 
cases, a joint action of both AP-N and DP IV could 
theoretically be possible for the removal of the X-Pro- 
sequence from the N-terminus or modification of the 
N-terminal part of these cytokines, respectively. 
In this context it is of interest that the biological 
activity of IL-la, IL-IS and IL-2 is changed strongly by 
short deletions or mutations at their N-terminal part 
[21-231. For IL-l/I it was shown that deletion of the four 
N-terminal amino acids leads to conformational 
changes and a lost of receptor binding capability as well 
as biological activity [24,25]. 
In the current work we have investigated the capabil- 
ity of DP IV and/or AP-N to modify the N-terminal 
part of some cytokines with susceptible sequences. We 
report here data showing that a number of synthetic 
oligopeptides with sequences analogous to the N-termi- 
nal part of natural and recombinant cytokines are de- 
graded by DP IV or by a combined action of AP-N and 
DP IV We also show, however, that the intact cytoki- 
nes, rIL-la, rIL-l/?, rIL-2, nIL-2 and G-CSF, are resis- 
tant to the action of these peptidases under in vitro 
conditions. 
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2. MATERIALS AND METHODS 
2.1. Enzymes and substrates 
DP IV (porcine kidney) was kindly provided by Dr. U. Demuth 
(Department of Biochemistry and Biotechnology, University of Halle- 
Wittenberg). AP-N was purified from human kidney according to the 
method described for DP IV by Rahfeld et al. [26] with an additional 
affinity purification step using rabbit anti-AP-N antibodies coupled 
to cyanogen bromide activated Sepharose 4B. 
Human IL-@(l-6), IL-2(-6), IL-2(1-12), IL-2( l-24), Met-IL-Z(l- 
6), Met-IL-2(1-12), l~photoxin(l-5), murine IL-6(1-12) and murine 
IL-ql-12)-polyoxyethyl~e (POE) were synthesized by solid-phase 
peptide synthesis by the Fmoc technique using peptide synthesizer 
431A (Applied Biosystems). An additional human IL-2(1-24) was 
provided by Dr. Conradt (Gesellschaft fiir Biotechnologische 
Forschung, Braunschweig). 0-Glycosylated IL-2 tetra-, hexa-, octa- 
and decapeptides (2-acetamido-2-desoxy-o-galactoseamine at Th?) 
were obtained from Prof. H. Paulsen (Department. of Organic Chem- 
istry, University of Hamburg). 
Recombinant IL-1s was a product of Pharma Biotechnologie Han- 
nover. Recombinant IL-la and recombinant IL-2 were produced by 
LaRoche, Basel. Natural IL-2 was kindly provided by Dr. J. Knilver- 
Hopf (DRK-Blutspendedienst Niedersachsen, Springe). Recombinant 
G-CSF was a kind gift of Prof. H. Welte (Medical School, Hannover). 
2.2. Hydrolys~ of pept~des by DP IV and/or AP-N 
Peptides (50 PM) were incubated with DP IV (2.6 mu/ml) in 0.01 
M phosphate buffer, pH 7.0, at 37°C. AP-N-catalyzed hydrolysis was 
studied under the same conditions and an AP-N concentration of 1.6 
mu/ml. The cytokines (5-1OOpM) were incubated with DP IV (up to 
2.6 U/ml) and/or AP-N (up to 4 U/ml) up to 72 h. 
The degradation of oligopeptides and cytokines and the generation 
of dipeptides and amino acids were measured by capillary electropho- 
resis and HPLC, respectively. 
2.3. Determination of K,,, and V_= 
For determination of K,,, and V_ six concentrations of each pep- 
tide in the range from 25 to 800 FM were incubated with 4.5 mu/ml 
DP IV in 0.01 M phosphate buffer, pH 7.0, at 37°C. Concentrations 
of the substrates were measured by capillary electrophoresis. The 
initial velocity of the hydrolysis reactions were calculated by fitting the 
data using Excel-Solver (Microsoft) and a first order reaction equa- 
tion. &, and V,, were calculated by fitting the V/S-characteristic 
using the Michaelis-Menten equation. 
2.4. Detection of peptides by capillary electrophoresis 
Peptides were analyzed by the method of capillary free zone electro- 
phoresis using the Biofocus 3000 system of Bio-Rad. The standard 
conditions for separation were: capillary = 25 pm x 24 cm, coated; 
load = pressure 20 psi x s-‘; run = 12 kV with 0.1 M phosphate buffer, 
pH 2.5; detection at 200 nm. 
2.5. Determ~ation of amino aciak by HPLC 
Determination of amino acids generated by AP-N-catalyzed hydrol- 
ysis was performed by detection of their u-pbthaldialdehyde deriva- 
tives at 330 nm. After deproteination of the samples, the amino acids 
were derivatized with o-phthaldialdehyde according to the method 
described in Pharmacia HPLC Application Note 497. For separation 
by reverse-phase chromatography a RoSil-Cl8 cohmm (Bio-Rad) and 
a 30 min phosphate buffer/acetonitril gradient were used. 
3. RESULTS 
3.1. Hydro~y~~~ of synthetic peptides with cytokine-hike 
sequences 
The investigated synthetic oligopeptides with se- 
quences analogous to the N-terminal part of natural 
human cytokines are summerized in Table I. 
All of the cytokine analogous oligopeptides tudied 
were found to be hydrolyzed by DP IV, generating the 
proline-containing dipeptide. The rate of degradation, 
however, was strongly influenced by the chain length 
and glycosyl residues. As shown particularly for inter- 
leukin-2 partial sequences, DP IV was capable of hy- 
drolysing N-terminal oligopeptides of IL-2 up to a chain 
length of at least 24 amino acids. Whereas the tetra- and 
Table I 
Investigated oligopeptides and cytokines 
Peptide Sequence Number of 
amino acids 
Hydrolysis by 
DP IV 
IL-l/9(1-6) 
IL-2(1-4)$ 
IL-2( I-5)g 
IL-2( l-6) 
IL-2( l-6)8 
IL-2(1-8)g 
IL-2( l-1O)g 
IL-2(1-12) 
IL-2( l-24) 
Met-IL-2(1-6) 
Met-IL-2(1-12) 
Lymphotoxin (1-5) 
murine X-6(1-12) 
murine IL-6(1-12)-POE 
rG-CSF 
rIL-la 
rIL-I#? 
nIL-2 
rIL-2 
APVRSL 6 
APT(g)S 4 
AI’T(g)SS 5 
APTSSS 6 
APT(g)SSS 6 
APT(g)SSSTK 8 
A~(g)SSSTKKT 10 
APTSSSTKKTQL 12 
A~SSSTKKTQLQLEHLLLDLQMI 24 
MAPTSSS 7 
MAPTSSSTKKTQL 13 
LPGVG 5 
FPTSQVRRGDFT 12 
FPTSQVRRGDFT-POE 12 
MTPLGPASSLP.. . 174 
FSFLSNV.. . 156 
APVRSLNCTL.. . 153 
APTSSSTKKT... 133 
MAPTSSSTKKT.. . 134 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
f 
hydrolysis by AP-N 
and DP IV 
hydrolysis by AP-N 
and DP IV 
+ 
+ 
+ 
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Fig. 1. DP IV hydrolysis of IL-2 oligopeptides with different chain 
lengths (50 PM). - -o- -, IL-2(1-4)g; - -o- -, IL-2(ld); -+--, IL-2 
(16)g; - + -, IL-2(1-8)g; - -x- -, IL-2(1-IO)g. DP IV activity = 2.6 
mU/ml. 
hexapeptides were totally degraded within 6 h, the de- 
capeptide needed more than 24 h for total hydrolysis by 
DP IV (2.6 mu/ml) (Fig. 1). IL-2(1-24) peptides were 
only hydrolyzed by < 10% within 48 h using a substrate 
concentration of 950 PM and a l,OOO-fold higher en- 
zyme concentration (2.6 U/ml, data not shown). A sim- 
ilar effect was observed for murine IL-6(1-12) and the 
IL-6 dodekapeptide coupled to polyoxyethylene (molec- 
ular weight approximately 4,500 Da). Whereas the free 
dodecapeptide was totally hydrolyzed within 4 h, the 
polymer-bound dodecapeptide was degraded by only 
5% within this time (not documented). 
Kinetic data were determined for glycosylated IL-2 
oligopeptides and for the non-glycosylated IL-lp and 
IL-2 hexapeptides (Table II). The V-/J&, values were 
negatively correlated with increasing molecular weight 
of the oligopeptides. Comparing glycosylated and non- 
glycosylated hexapeptides, it could be shown that glyco- 
sylation at the Thr3 has a negative effect on the velocity 
of hydrolysis of these oligopeptide by DP IV. 
A number of recombinant cytokines expressed in bac- 
teria exhibit methionine at their N-terminus. Therefore, 
we studied the cleavage of a methionine residue from 
this position by AP-N. Using synthetic hepta- and 
tridekapeptide with the N-terminal sequence of human 
rIL-2, we could demonstrate that AP-N is able to split 
off the N-terminal methionine from these oligopeptides 
(not shown). No degradation was found with DP IV 
Using IL-2(1-12) without methionine in the first posi- 
tion, it could be demonstrated that Ala-Pro is removed 
totally after 2 h by DP IV. Combined treatment of this 
oligopeptide by both enzymes leads to total degrada- 
tion. A concerted action of AP-N and DP IV was also 
shown in the case of hydrolysis of the murine IL-6(1-12) 
dodekapeptide (not documented). 
3.2. Treatment of several cytokines by soluble 
and AP-N 
DP IV 
The N-terminal sequences of the natural and recom- 
binant cytokines studied with respect o degradation by 
DP IV and/or AP-N are summerized in the lower part 
of Table I. 
Studying the hydrolysis of these cytokines at concen- 
trations in the range of 10-6-10-4 M by DP IV and 
AP-N alone as well in combination, we found no degra- 
dation even at enzyme concentrations up to l,OOO-fold 
higher (maximal 4 U/ml and 2.6 U/ml for AP-N and DP 
IV, respectively) than in the experiments described 
above with the oligopeptides. This holds true for data 
obtained by capillary electrophoresis as well as by 
HPLC determination of the amino acids. 
These results strongly suggest hat, in contrast to oli- 
gopeptides, intact cytokines such as IL-la, IL-lp, IL-2 
and G-CSF, seem to be resistant o the action of soluble 
DP IV and AP-N. 
4. DISCUSSION 
Oligopeptides with the N-terminal sequences of se- 
lected cytokines, such as human IL-lp, IL-2, lympho- 
toxin and murine IL-6, were studied with respect to 
their degradability by DP IV and AP-N. We could dem- 
onstrate that different N-terminal oligopeptides of these 
cytokines are suitable substrates for the DP IV The 
hydrolysis rate of these types of peptides was found to 
be negatively correlated to their chain length or molec- 
ular weight, respectively. This is in line with data of 
Nausch et al. [27] who studied the DP IV-catalyzed 
degradation of different biological active peptides, e.g. 
substance P, /?-casomorphine, trypsinogen and mono- 
meric fibrin, as well as intact nIL-2. In contrast to these 
data, however, Bongers et al. [28] reported that in the 
case of growth-hormone releasing factor, the hydrolysis 
rate by DP IV of longer peptides (44 amino acids) is 
higher than that of shorter peptides (3 and 11 amino 
acids). 
Cytokine-analogous oligopeptides with an additional 
N-terminal methionine were included in our studies be- 
cause N-terminal methionine is present in many recom- 
binant cytokines. Our data show that AP-N is able to 
remove methionine from oligopeptides, and that a con- 
Table II 
Kinetic constants of DP IV-catalyzed hydrolysis of peptides with 
cytokine partial sequences 
Substrate Number Molecular X, vmax vmaJ&n 
of amino weight Qmol) @moV (min-‘) 
acids min) 
IL-2( 1-6) 6 548.6 51 3.5 0.061 
IL-2(14)g 4 581.6 27 1.9 0.070 
IL-lfi(ld) 6 641.8 64 2.4 0.037 
IL-2( l-5)g 5 668.1 75 1.2 0.016 
IL-2(1-6)g 6 155.8 65 1.5 0.023 
IL-2( 1-8)g 8 985.0 19 0.335 0.018 
IL-2(1-1O)g 10 1,214.3 199 0.91 0.005 
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certed action of AP-N and DP IV results in their total 
degradation. 
However, in contrast to oligopeptides with a chain 
length of up to 24 amino acids, intact cytokines such as 
rIL-la, rIL-l/?, rIL-2, nIL-2 and G-CSF, were found to 
be resistant o hydrolysis by purified DP IV and AP-N 
alone as well as in combination. These data obtained 
with natural and recombinant cytokines, as well as the 
results concerning glycosylated peptide sequences of IL- 
2, are in contradiction to the hypothesis discussed by 
Nausch [27] which states that glycosylation of natural 
IL-2 should be the reason for its stability against hy- 
drolysis by DP IV The most probable explanation for 
this resistance might be a limited or lack of susceptibility 
to the N-terminal part of the investigated cytokines for 
these enzymes under experimental conditions. Analysis 
of the 3D structures of IL-la, IL-l/I and IL-2, however, 
demonstrated that the N-terminal part of these cytoki- 
nes is on the outside of the molecule, i.e. on the surface, 
and should be accessible to the exopeptidases [22,29]. 
Obviously additional steric factors influence their sus- 
ceptibility to soluble exopeptidases. 
Our data suggest hat hydrolysis of cytokines by cel- 
lular exopeptidases needs possibly one or more preced- 
ing endoproteolytic steps, and DP IV and AP-N could 
play a role in modification of the generated N-terminal 
peptides with the conserved proline in the second or 
third position. For IL-1s it was shown by Obal [30], 
Palaszynski [31] and Boraschi [32], that oligopeptides 
with different internal subsequences of these cytokines 
had different IL-l/? activities. Investigations with N-ter- 
minal subsequences are lacking as yet. With regard to 
preceding endoproteolysis, data published by Bauvois 
et al. [9] are also interesting; they reported that DP IV 
is involved in the hydrolysis of an 8 kDa cleavage prod- 
uct of TNF-a generated by the action of other pepti- 
dases on a membrane preparation of U937 cells. As an 
alternative mechanism for influencing the susceptibility 
of cytokines to exopeptidase-catalyzed processing, con- 
formational changes due to binding of these factors to 
their specific receptor can not, as yet, be excluded. 
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